Astrazeneca has pushed back the release of results for a key lung cancer drug trial.
The pharmaceuticals giant originally said the findings would be revealed in the first half of 2018 but said yesterday they will be announced in the second half.
Known as ‘Mystic’, the trial will show whether its Imfinzi drug gives patients with non-small cell lung cancer a better chance of survival.
Initial results in July showed a combination of Imfinzi with another drug, tremelimumab, was no more effective than chemotherapy, sending shares plunging by 16 per cent in a day.
Astra said: ‘Based on current predictions, the final analysis of overall survival is now expected in the second half of 2018, previously anticipated in the first half.’
The Mystic trial is being conducted at 167 facilities across 17 countries.
Lung cancer is the biggest cause of cancer death among men and women, accounting for roughly one third of deaths related to the disease.
THIS IS MONEY’S FIVE OF THE BEST SAVINGS DEALS
Paragon pays 1.45% interest on its one-year fixed rate Isa account. Interest can be payed monthly or yearly. It requires a minimum deposit of £500.
The AA pays a top rate of 1.16% AER on its easy access Isa account. The account comes with a 12-month 0.96% rate bonus so remember to find a better account before the rate drops. Minimum deposit is £100.
Masthaven offers a Flexible Saver which lets you set your own term. It pays a top rate of 1.95% AER interest on its 18-month fixed rate bond. The minimum deposit is £500.
Nationwide pays a top rate of 1.4% AER variable interest on its Loyalty Single Access Isa Saver if you have been a customer for a year or more. If you make more than one withdrawal interest drops to 0.5%.
RCI Bank pays 1.3% AER variable interest on its easy access deal. Deposits in its Freedom Savings Account have no FSCS protection, but you are covered for up to €100,000 by the French equivalent (FGDR).